Revvity Inc vs Solstice Advanced Materials Inc. Common Stock — how do they compare? Revvity Inc trades at $151.84 (market cap $17.30B), while Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.68B). The key difference: Revvity Inc is the larger of the two by market cap, and Solstice Advanced Materials Inc. Common Stock pays the higher dividend (0.49%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and Solstice Advanced Materials Inc. Common Stock for 0 Days on average.
| RVTY | SOLS | |
|---|---|---|
Market Cap | $17.30B | $9.68B |
Volume | 1,387,588 | 1,519,067 |
Sector | Health | Basic Materials |
52-Week High | $157.36 | $88.60 |
52-Week Low | $82.26 | $41.43 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $19.62B | $11.35B |
Dividend Yield | 0.18% | 0.49% |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →